

EVALUATION OF STAPHYLOCOCCAL ACTIVITY OF *GARCINIA KOLA* ALMONDS

Abstract

The emergence of infectious diseases, particularly staphylococcal infections, treatment failures and the more high cost of treatment of infections caused by resistant staphylococci called to find other care alternatives. This study was initiated to evaluate the antibacterial activity of the aqueous extract from *Garcinia kola* almonds on the *in vitro* growth of *Staphylococcus aureus* strains. The methods of diffusion in agar and liquid media were used for susceptibility testing and MIC and MBC determination. The tests were performed on four strains of *S. aureus* and one reference strain. The minimum inhibitory concentrations of the extracts ranged from 3.12 mg/mL and 12.5 mg/mL and the minimum bactericidal concentrations between 6.25 mg/mL and 25 mg/mL. The lowest value of MIC and MBC was observed with *S. aureus* ATCC 29213 while the greatest value of these same parameters was obtained on *S. aureus* 993C/18 and *S. aureus* 1075C/18. The aqueous almonds extract of *Garcinia kola* had a bactericidal activity on all the strains of *S. aureus* studied. This could justify the use of *Garcinia kola* almonds in the treatment of various diseases in traditional society.

Key words: *Garcinia kola*, aqueous extract, *Staphylococcus aureus*, MIC, MB

INTRODUCTION

Infectious diseases are nowadays the cause of nearly 17 million deaths a year and are a major preoccupation for health workers (Simpore *et al.*, 2006). In developing countries, they account for 45% of deaths, of which 14.2% in Côte d'Ivoire (Walsh, 2003). These infections include severe skin diseases and mucous membranes such as endocarditis and sepsis caused by bacteria of *Staphylococcus* genus (Duval 1989). The prevalence of nosocomial and community-acquired staphylococcal infections is increasing steadily. However, the treatment of these infections has become increasingly difficult because of the emergence of multi-resistant strains (Mougeot *et al.*, 2001). In addition, *Staphylococcus aureus* is currently one of the leading causes of nosocomial infection worldwide because 10-50% of *S. aureus* strains isolated in hospitals are resistant to meticillin, including vancomycin, the glycopeptide used against methicillin-resistant strains (Kopp *et al.*, 2004). The ability of *S. aureus* to develop multiple resistance to antibiotics increasingly limits therapeutic possibilities and thus poses a serious public health problem (Accarias, 2014). Otherwise, conventional antibiotics used against microbial diseases are expensive, difficult to access by poor people and are still not

34 effective and appropriate (Bennet *et al.*, 2000). They sometimes have high side effects on
35 human health whose targets are the heart, liver, kidneys, blood (Odds *et al.*, 2003). To fight
36 against pathogenic microorganisms, the search for new natural phytomedicines has become
37 an emergency for ethnopharmacologists, botanists, pharmacists and microbiologists (Kavitha
38 and Padma, 2008). Efforts in this area have focused on plants because of their multiple use
39 by a large portion of the world's population (Akinnibosun *et al.*, 2008). It is within this
40 framework, that we are interested in *Garcinia kola* whose study will contribute to the
41 valorization of the Ivorian medicinal plants. This plant is used by people as an aphrodisiac
42 and also in the traditional treatment of gastritis, stomach upset and many other pathologies
43 (Odebunmi *et al.*, 2009).

44 I-Material and methods

45 1.1-Plant material

46 The plant material used consists of *Garcinia kola* almond powder. These almonds were
47 harvested in August, 2018 on the market of ELIBOU (located on the North Highway about
48 79 kilometers from Abidjan). The almonds have been grated and dried out of the sun at
49 laboratory temperature (25 to 30 ° C) for 15 days. Once dried, they have been reduced to a
50 fine powder using a GM 300 type Retsch grinder. The powders obtained were stored in
51 sealed flasks. These powder were used for the preparation of plant extracts.

52 1.2-Bacterial material

53 Several strains of *S. aureus* were used including one reference strain and four others of
54 different profile provided by the Bio Bank of the Institut Pasteur Côte d'Ivoire (Table I).

55 Table I: Profile of the bacteria tested.

Strains	Profile
<i>S. aureus</i> ATCC 29213	β -lactam reference strains
<i>S. aureus</i> 993C/18	β -lactam resistant strain
<i>S. aureus</i> 1074C/18	Methicillin resistant strain
<i>S. aureus</i> 1075C/18	Wild strain
<i>S. aureus</i> 1076C/18	Wild strain with β -lactam

56

57 2-Methods

58 2.1-Preparation of the aqueous extract

59 It was carried out according to the method described by **Ackah *et al.* (2008)**. The powder
60 (100 g) of *Garcinia kola* was dissolved in 1000 ml of distilled water and then homogenized in
61 a Blender at room temperature. The homogenate obtained was first wrung out in a square of
62 white fabric. Then, doubly filtered on hydrophilic cotton and once on whatman paper 3 mm.
63 The filtrate obtained was dried in an oven at 50 ° C. for 48 hours. The mass of extract
64 obtained was stored in sterile, clean, dry flasks then kept out of from heat and moisture. The
65 percentage of the extraction yield was calculated according to the following formula:

66

$$67 \quad \text{Extraction yield (\%)} = \frac{\text{Mass of dried extract x100}}{\text{Mass of plant powder used}}$$

68

69 2.2-Antibacterial tests

70 2.2.1-Preparation and Seeding of the Concentration Range

71 The concentration range of the plant extract was prepared in seven test tubes numbered from
72 1 to 7 by the double dilution method according to a geometric progression of 1/2 reason. In a
73 series of eight hemolysis tubes numbered C1 to C8, 1mL of pure inoculum was introduced.
74 Then, 1mL of plant extract was added to the tubes according to the prepared concentration
75 range. This distribution of plant extract was made so that 1mL of 200 mg/mL plant extract
76 was transferred into the C1 tube. Tube C2 received 1 mL of 100 mg/mL and so on until tube
77 C7 received 1mL of the 3.125 mg/mL solution. The C8 tube received instead of the plant
78 extract, 1 ml of sterile BMH which was used as a growth control. As a result of the
79 volume/volume dilution achieved, the concentration in the tubes was reduced by half. These
80 tubes were incubated at 37°C for 24 hours. (**Toty *et al.*, 2013**).

81

82 2.2.2-Preparation of the bacterial inoculum

83 The bacterial inoculum was prepared according to the method described by (Toty *et al.*,
84 2013). The bacterial inoculum was prepared from an isolated 18-hour colony in 10 mL Mueller
85 Hinton broth (MHB) and incubated for 3 to 5 hours at 37°C to obtain a pre-culture. A volume of 0.1

86 mL was collected and added to 10 mL of BMH twice concentrated. This bacterial suspension is
87 evaluated at about 10^6 cells/mL and constitutes the 10^0 dilution or pure inoculum.

88

89 **2.2.3-Sensitivity test**

90 The agar diffusion technique was used to study the sensitivity tests. Mueller Hinton medium,
91 poured and dried in a petri dish, was flooded with 3 mL of inoculum. Then, using a sterile
92 die, wells about 6 mm in diameter were drilled into the agar. Each well received 80 μ L of the
93 test substance at a concentration of 100 mg/mL. The Petri dishes were incubated at 37°C for
94 24 hours, after 30 minutes of diffusion at laboratory temperature. The presence or absence of
95 an inhibition zone was observed and the inhibition diameter was measured. Oxacillin was
96 used as a control. The interpretation was made according to **Ponce *et al.* (2003)**.

97

98 **2.2.4-Antibacterial parameters MIC and MBC.**

99 Minimal Inhibitory Concentration (MIC) was the lowest concentration of the plant extract for
100 which there is no visible growth to the naked eye after 24 hours of incubation. His
101 determination was made by observation of the disorder induced by the growth of the germs
102 present in each tube. From the MIC, the smallest concentration that allows only 0.01% of
103 bacteria in suspension to survive in 24 hours corresponds to CMB. It is determined by
104 spreading on a solid medium of 2 μ L of the contents of each tube of concentration greater
105 than or equal to the MIC (**Soussy *et al.*, 2012**).

106

107 **2.3-Statistical Analyzes**

108 All results were repeated three times. The data was processed using the Graph Pad Prism 5.0
109 software (Microsoft, USA). Statistical analysis of the results was performed using Anova
110 One-Way. The value of the averages is accompanied by the standard error on the mean (mean
111 \pm SEM).

112

113 **3-Results**

114 **3.1-Extraction**

115 The yield, appearance and color of the aqueous extract of *Garcinia kola* almonds are shown
116 in Table II. This extract in powder form, of brown color obtained a yield of 6.36%.

117 Table II: Color, appearance and yield of the aqueous extract of *Garcinia kola* (clusiaceae).

Characteristics			
	Color	Appearance	Yield (%)
aqueous extract	Brown	Powder (not very pasty)	6,36 %

118

119

120 **3.2-Antibacterial effects**

121 **3.2.1-Sensitivity test**

122 The values of the inhibition diameters of the *G. kola* extract and of the reference molecule are
123 shown in Tables III and IV. The plant extract recorded inhibition diameters ranging from
124 10.00 ± 0.00 mm to 16.33 ± 0.58 mm. The largest diameter values (16.33 ± 0.58 mm, $15.66 \pm$
125 0.58 mm and 15.33 ± 0.58 mm) were obtained with *S. aureus* 993C / 18, *S. aureus* ATCC
126 29213 and *S. aureus* 1074C / 18 respectively, while *S. aureus* 1076C / 18 and *S. aureus*
127 1075C / 18 exhibited smaller values (13.33 ± 1.53 mm and 13.00 ± 2.00 mm). These
128 diameters remain lower than those obtained by the reference molecule (oxacillin).

129

130

131 **Table III: Inhibition diameters (mm) induced by the aqueous extract**

Strains	Concentrations (mg/mL)							
	200	100	50	25	12,5	6,25	3,12	1,56

<i>S. aureus</i> ATCC 29213	15,66 ± 0,58	13,00 ± 0,00	11,67 ± 0,58	10,00 ± 0,00	6,00 ± 0,00	6,00 ± 0,00	6,00 ± 0,00	6,00 ± 0,00
<i>S. aureus</i> 993C/18	16,33 ± 0,58	14,33 ± 0,58	12,00 ± 0,00	11,00 ± 0,00	6,00 ± 0,00	6,00 ± 0,00	6,00 ± 0,00	6,00 ± 0,00
<i>S. aureus</i> 1074C/18	15,33 ± 0,58	12,67 ± 1,15	11,00 ± 1,00	10,00 ± 1,00	6,00 ± 0,00	6,00 ± 0,00	6,00 ± 0,00	6,00 ± 0,00
<i>S. aureus</i> 1075C/18	13,00 ± 2,00	11,67 ± 1,53	10,67 ± 0,53	6,00 ± 0,00	6,00 ± 0,00	6,00 ± 0,00	6,00 ± 0,00	6,00 ± 0,00
<i>S. aureus</i> 1076C/18	13,33 ± 1,53	12,00 ± 1,00	11,00 ± 1,00	10,00 ± 0,00	6,00 ± 0,00	6,00 ± 0,00	6,00 ± 0,00	6,00 ± 0,00

132 6,00±0,00: corresponds to the wells diameters

133

134

135

136

137 **Table IV: Inhibition diameters (mm) induced by the antibiotic (Oxacillin)**

Strains	Concentrations (mg/mL)														
	62,50	31,25	15,63	7,81	3,91	1,95	0,98	0,49	0,24	0,12	0,061	0,031	0,016	0,008	0,004
<i>S. aureus</i> ATCC 29213	>52	>52	>52	>52	>52	>52	>52	>52	34	28	21	21	18	6,00	6,00
									± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00
<i>S. aureus</i> 993C/18	50	49	48	46	43	40	38	36	32	26	25	22	19	6,00	6,00
	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00
<i>S. aureus</i> 1074C/18	39	39	35	35	33	32	30	28	28	26	22	18	6,00	6,00	6,00
	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00
<i>S. aureus</i> 1075C/18	52	51	46	45	43	40	38	35	30	28	24	21	18	6,00	6,00
	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00
<i>S. aureus</i> 1076C/18	46	43	40	38	35	34	33	28	25	22	16	6,00	6,00	6,00	6,00
	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00	± 0,00

138 6,00±0,00: corresponds to the wells diameters

139 **3.2.2-Determination of antibacterial activity**

140 The results of the antibacterial parameters obtained are mentioned in Tables V and VI.
 141 Analysis of the results of the tables revealed that MICs obtained on *S. aureus* strains ranged
 142 from 3.12 ± 0.00 mg / mL to 12.50 ± 0.00 mg / mL. The lowest MIC value was observed for
 143 *S. aureus* ATCC 29213 (3.12 ± 0.00 mg / mL) and the highest value was obtained with *S.*
 144 *aureus* 993C / 18 and *S. aureus* 1075C / 18 (12.5 ± 0.00 mg / mL). As for MBC, the recorded
 145 values ranged from 6.25 ± 00 to 25 ± 00 mg / mL. This made it possible to determine the
 146 MBC / MIC ratio. The aqueous extract of *G. kola* obtained MBC / MIC ≤ 2 on all the strains
 147 of *S. aureus* (Table V). However, this ratio varied from 2 to 4 with the reference molecule
 148 Table VI.

149

150 **Table V: Antibacterial Parameters of the Aqueous Extract**

Strains	Antibacterial parameters (mg/mL)		Ratio efficacy (MBC / MIC)	Effect
	MIC	MBC		
<i>S. aureus</i> ATCC 29213	$3,12 \pm 0,00$	$6,25 \pm 0,00$	2	Bactericidal
<i>S. aureus</i> 993C/18	$12,5 \pm 0,00$	$25 \pm 0,00$	2	Bactericidal
<i>S. aureus</i> 1074C/18	$6,25 \pm 0,00$	$12,5 \pm 0,00$	2	Bactericidal
<i>S. aureus</i> 1075C/18	$12,5 \pm 0,00$	$25 \pm 0,00$	2	Bactericidal
<i>S. aureus</i> 1076C/18	$6,25 \pm 0,00$	$6,25 \pm 0,00$	1	Bactericidal

151

152

153

154

155

156

157 **Table VI: Antibacterial parameters of the antibiotic (oxacillin).**

Strains	antibactericidal parameters (mg/mL)		Ratio efficacy (MBC / MIC)	Effect
	MIC	MBC		
<i>S. aureus</i> ATCC 29213	15,63± 0,00	31,25± 0,00	2	Bactericidal
<i>S. aureus</i> 993C/18	7,81± 0,00	31,25± 0,00	4	Bacteriostatic
<i>S. aureus</i> 1074C/18	7,81± 0,00	31,25± 0,00	4	Bacteriostatic
<i>S. aureus</i> 1075C/18	15,63± 0,00	62,5± 0,00	4	Bacteriostatic
<i>S. aureus</i> 1076C/18	3,91± 0,00	7,81± 0,00	2	Bactericidal

158

159

160 **4-Discussion**

161 The present study was initiated with the aim of evaluating the antibacterial activity of the
162 aqueous extract of *Garcinia kola* almonds on the *in vitro* growth of *Staphylococcus aureus*
163 strains. During this study, distilled water was used as an extraction solvent. The extraction
164 yield (6.36%) obtained from our study is less than 8.8% recorded by **Yété et al. (2015)** during
165 the aqueous extraction of almonds from this same plant. The observed variation in yield
166 could be related to several parameters. Indeed, several authors have reported that the
167 extraction yield may depend on several factors such as the time of harvest of the plant, the
168 plant age, the drying procedure, the solvent, the pH, the temperature, the extraction time and
169 sample composition (**Quy et al., (2014), Stalikas (2007)**). With regard to the antibacterial
170 effects, the results obtained show that the aqueous extract of *G. kola* almonds has an
171 inhibitory activity against the *in vitro* growth of staphylococci with a different degree related
172 to the profile of the strains. All strains of *S. aureus* studied were sensitive to the aqueous *G.*
173 *kola* extract. These results are similar to those obtained by **Akerele et al. (2008)**. These

174 authors recorded inhibition diameters of 20 ± 2.4 mm on *S. aureus* strains. Overall, *S. aureus*
175 993C / 18 was more sensitive to the extract studied. However, the inhibition diameters
176 induced by the aqueous extract remain lower than those of the reference antibiotic. Regarding
177 to the measurement of antibacterial activity, it should be recalled that when the MBC / MIC
178 efficacy ratio of an antibacterial substance is less than or equal to two (≤ 2), the latter is
179 described as a bactericidal substance. If the MBC / MIC ratio is greater than two (> 2), then it
180 is called bacteriostatic (Fauchere and Avril, 2002). In view of this principle, the aqueous
181 extract of *G. kola* has a bactericidal effect on all the strains studied. Our results corroborate
182 those of Morabandza *et al.* (2014). These authors have indicated that the aqueous extract of
183 *G. kola* mesocarp has a bactericidal effect on *S. aureus* strains. Similar results were also
184 obtained in the *Harungana madagascariensis* study (Toty *et al.*, 2013). However, the
185 comparison of the performance of our extract with that of the control (oxacillin), indicates
186 that the aqueous extract is bactericidal on all strains of *S. aureus* tested while oxacillin is
187 bactericidal on *S. aureus* ATCC 29213 and *S. aureus* 1076C / 18 but bacteriostatic on the
188 other strains. This indicates that the aqueous extract of *G. kola* has better antibacterial activity
189 than oxacillin. This bactericidal effect of the aqueous extract of *G. kola* could be explained by
190 the presence of secondary metabolites found therein namely alkaloids, anthraquinones,
191 flavonoids, saponosides, tannins, terpenes and steroids (Morabandza *et al.* 2013). Studies
192 have shown that flavonoids are good inhibitors of the sortases, enzymes found in the
193 cytoplasmic membrane of Gram-positive bacteria that catalyze all surface proteins (adhesins
194 and internalins) (Cushnie and Lamb, 2011). According to these authors, epigallocatechin
195 prevents the secretion of coagulase and *S. aureus* α -toxin. Flavonoids also inhibit the release
196 of virulence factors of this bacterium (Ghedadba *et al.*, 2015). The synergistic actions at
197 various levels of the secondary metabolites would be at the base of the antibacterial activity
198 of the extract. The results obtained during this study have justified the use of this plant in
199 traditional medicine.

200

201 **Conclusion**

202 The *in vitro* study of the aqueous extract of almonds of *G. kola* made it possible to highlight
203 the antibacterial properties of this plant on the growth of the staphylococcal germs studied.
204 The results obtained reveal the presence of antibacterial active principles in the aqueous
205 extract of *G. kola* almonds. The results showed a bactericidal effect of the extract studied on

206 these strains of *S. aureus*. This bactericidal effect observed is dose dependent. The sensitivity
207 of staphylococcal strains to the aqueous extract of *G. kola* almonds is of great importance in
208 the treatment of pathologies associated with them. The present results justify certain
209 ethnopharmacological uses. They demonstrate that this plant can be used to treat infectious
210 diseases of staphylococcal origin. In view of the results, it would be interesting to undertake
211 studies to evaluate the toxicity and then purify the extract of this plant to consider the
212 development of improved traditional medicines.

213

214 **Bibliographical references:**

215 **Accarias S.** Impact du phénotype des macrophages résidents sur la nature de la réponse
216 inflammatoire précoce lors d'une infection par *Staphylococcus aureus*. Thèse de Doctorat,
217 Université de Toulouse, France, **2014**.

218 **Ackah J. A. A. B., Kra A. K. M., Zirihi G. N. & Guédé-Guina F.** Evaluation de l'activité
219 antifongique de tekam, un extrait de plante, sur la croissance *in vitro* de *candida albicans*.
220 *Revue Ivoirienne Sciences Technologiques*, **2008**; 11: 119-129.

221 **Akerele J. O., Obasuyi O., Ebomoyi M. I., Oboh I. E. & Uwumarongie O. H.**
222 Antimicrobial activity of the ethanol extract and fractions of the seeds of *Garcinia kola*
223 Heckel (Guttiferae). *African Journal of Biotechnology*, **2008**; 7: 169-172.

224 **Akinnibosun H. A., Akinnibosun F. I. & German B. E.** Antibacterial activity of aqueous
225 and ethanolic leaf extracts of *Peperomia pellucida* (L.) H. B. & K. (*piperaceae*) on three
226 gram-negative bacteria isolates. *Science World Journal*, **2008**; 3: 33-36.

227 **Bennet D. M., Bhandol P. and Leitch I. J.** Nuclear DNA amounts in
228 angiosperms and their modern Uses 807 new estimates. *Annals of Botany*, **2000**; 86: 859-909.

229 **Cushnie T.P.T. & Lamb A;J.** Recent advances in understanding the antibacterial properties
230 of flavonoïds. *Internat J Antimicrob Agents*, **2011**; 1-9

231

232 **Duval J.** Evolution des résistances. *In: LE MINOIR L et VERON M, eds. Bactériologie*
233 *médicale. Flammarion Paris (France), 1989*.

234 **Fauchere J. L. & Avril J. L.** Bactériologie Générale et Médicale, Edition Ellipses, Paris
235 (France), **2002**.
236

237 **Ghedadba N. Hambaba L. Ayachi A. Aberkane M. C. Bousselsela H. Oueld-Mokhtar S.**
238 **M.** Polyphénols totaux, activités antioxydante et antimicrobienne des extraits des feuilles de
239 *Marrubium deserti* de Noé. *Phytothérapie*, **2015**; 1-12.
240

241 **Kavitha D. & Padma P. R.** Biotherapeutic potential of flower and bark extracts of
242 *Couroupita guianensis* Aubl. *Plant Archives*, **2008**; 8: 569-771.

243 **Kopp B. J., Nix D. E. & Armstrong E. P.** Clinical and economic analysis of methicillin
244 susceptible and -resistant *S. aureus* infections. *Annals of Pharmacotherapy*, **2004**; 38: 1377-
245 1382.

246 **Morabandza C. J., Okemy A. N., Ongoka R. P., Okiemy-Akieli M. G., Attibayeba A. &**
247 **Abena A. A.** Effets antimicrobiens, anti-inflammatoires et antioxydants du mésocarpe de
248 *Garcinia kola* Heckel (Clusiaceae). *Phytothérapie*, **2014**; 12: 164-169.

249 **Mougeot C., Guillaumat-Taillet .Y. & Libert J. M.** *Staphylococcus aureus*: nouvelle
250 détection de la résistance intrinsèque par la méthode de diffusion. *Pathologie biologique*, **2001**;
251 49: 199-204.

252 **Odds F.C., Brown A.J.P., Gow N.A.R.** Antifungal agents: Mechanisms of action. *Trends in*
253 *Microbiology*, **2003**; 11: 272-279.

254 **Odebunmi E. O., Oluwaniyi O. O., Awolola G. V. & Adediji O. D.** Proximate and
255 nutritional composition of kola nut (*Cola nitida*), bitter cola (*Garcinia kola*) and alligator
256 pepper (*Aframomum melegueta*). *African Journal of Biotechnology*, **2009**; 8: 308-310.

257 **Ponce A. G., Fritz R., Del Alle C. & Roura S.I.** Antimicrobial activity of essential oil on
258 the native microflora of organic Swiss chard. *Lebensmittel-Wissenschaft und Technologie*,
259 **2003**; 36: 679-684.

260 **Quy Diem Do., Angkawijay A. E., Tran-Nguyen P. L., Huynh L. H., Soetaredjo F. E.,**
261 **Isadj S., & Ju Y-H.** Effect of extraction solvent on total phenol content, total flavonoids
262 content, and antioxidant activity of *Limnophila aromatica*. *Journal of Food and Drug*
263 *analysis*, **2014**; 22: 296-302.

264 **Simporé J., Pietra V., Savadogo A., Pignatelli S., Nikiema J. B., Nadembega W. M.,**
265 **Yara J., Zoungrana N., Bakouan D., Colizzi V., Castelli F. & Musumeci S.** Reduction of
266 mother in to child transmission of HIV at Saint Camille Medical Centre in Burkina Faso.
267 *Journal of Medical virology*, **2006**; 78: 148-152.

268 **Stalikas C. D.** Extraction, separation, and detection methods for phenolic acids and
269 flavonoids. *Journal of Separation Science*, **2007**; 30: 3268-3295.

270 **Soussy C. J., Cavallo J. D., Courcol R., Drugeon H., Fabre R. & Jarlier V.** Sensibilité
271 aux antibiotiques des souches d'*Escherichia coli* isolées en 1998 et 1999: résultats d'une
272 enquête multicentrique française. *Médecine et Maladies Infectieuses*, **2000**; 30: 650-656.

273

274 **Toty A. A., Guessennd N., Bahi C., Kra A. M., Otokore D. A. & Dosso M.** Évaluation *in-*
275 *vitro* de l'activité antibactérienne de l'extrait aqueux de l'écorce de tronc de *Harungana*
276 *madagascariensis* sur la croissance de souches multi-résistantes. *Bulletin de la Société Royale*
277 *des Sciences de Liège*, **2013**; 82: 12-21

278

279 **Walsh C.** Antibiotics: actions, origins, resistance. *American Society for Microbiology*,
280 Washington, D. C (USA), **2003**.

281 **Yété P., Togbé A., Koudoro Y., Agbangnan P., Ndahischimiye V., Djènantin T. S.,**
282 **Wotto D, Azandégbé E. C. & Sohounhloue D.** Etude comparative des Composés
283 phénoliques et activité antiradicalaire des extraits des Graines de *Garcinia kola* (Guttiféreae)
284 et de *Cucumeropsis edulis* (cucurbitacéae) du Bénin. *International Journal of Innovation and*
285 *Scientific Research*, **2015**; 15: 217-227.

286